top of page

GlaxoSmithKline seeks US approval for shingles vaccine Shingrix

The company submitted a biologics licence application (BLA) to the US Food and Drug Administration (FDA) to market the vaccine for the prevention of herpes zoster (shingles) in people aged 50 years or more.




Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page